TICKERNERD
Menu
CVSCVSHealthcare · Healthcare Plans

CVS Stock Forecast: CVS Health Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$105
+0.90% on the day

The 28 Wall Street analysts covering CVS Health Corp. hold a median 12-month price target of $113 — +7.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$133.2B
Ticker Nerd rank
83 / 100
Median analyst target
$113
Analysts covering
28
Total return, dividends reinvested
1W
−1.6%
1M
+1.2%
YTD
+35.9%
1Y
+74.0%
From 52W high
−4.1%
From 52W low
+76.9%
$60
$110
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CVS Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Momentum
92
Volatility
90
Issuance
80
Value
72
Accruals
67
Growth
61
Quality
21
Size
2

Revisions (94): Analysts have, on balance, been raising their forecasts.

Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own CVS Health Corp. — and when they’d sell — is the membership.

Wall Street

CVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CVSHigh $148Median $113Low $79

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
24 Buy4 Hold0 Sell
Low $79Median $113High $148

The green dot is the last close — the median target sits +7.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
25 July 2026UBSMaintainsBuy—
24 July 2026UBSMaintainsBuy$115 → $122
14 July 2026Truist SecuritiesMaintainsBuy—
14 July 2026Truist SecuritiesMaintainsBuy$108 → $118
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$103 → $123
9 July 2026RBC CapitalMaintainsOutperform—
9 July 2026RBC CapitalMaintainsOutperform$107 → $113
7 July 2026Cantor FitzgeraldMaintainsOverweight—
7 July 2026Cantor FitzgeraldMaintainsOverweight$100 → $110
23 June 2026B of A SecuritiesMaintainsBuy—
8 June 2026MizuhoMaintainsOutperform—
4 June 2026Morgan StanleyMaintainsOverweight—
1 June 2026Truist SecuritiesMaintainsBuy—
26 May 2026BarclaysMaintainsOverweight—
20 May 2026MizuhoMaintainsOutperform—
14 May 2026Morgan StanleyMaintainsOverweight—
13 May 2026BernsteinMaintainsOutperform—
12 May 2026JP MorganMaintainsOverweight—
11 May 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

CVS Health Corp. (CVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
45.8×

Cheaper than 17% of US stocks

Price / sales
0.3×

Cheaper than 88% of US stocks

Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
13.0×

Cheaper than 29% of US stocks

Growth & margins
Revenue growth (YoY)
6.1%

Higher than 44% of US stocks

Earnings growth (YoY)
65.4%

Higher than 81% of US stocks

Gross margin
15.6%

Higher than 16% of US stocks

Operating margin
4.1%

Higher than 56% of US stocks

Net margin
0.7%

Higher than 48% of US stocks

Returns & dividend
Return on equity
3.8%

Higher than 51% of US stocks

Return on assets
2.7%

Higher than 64% of US stocks

Dividend yield
2.5%

Higher than 56% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CVSCVS Health Corp.$133.2B
83
ELVElevance Health, Inc.$83.5B
62
CIThe Cigna Group$73.8B
53
UNHUnitedHealth Group, Inc.$375.4B
77
HUMHumana, Inc.$43.8B
44
CNCCentene Corp.$30.6B
89
MOHMolina Healthcare, Inc.$10.1B
30
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CVS news & analysis

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research · 3 Aug 2026positive

Zacks Investment Research reported that CVS Health has a strong earnings surprise history and currently possesses the two key ingredients for a likely earnings beat in its next quarterly report.

Why it matters — Investors watching CVS would care because the analysis suggests the company may deliver another positive earnings surprise, which could influence market sentiment around the stock.

CVS Health's Q2 Earnings on Deck: How Should You Play the Stock?

Zacks Investment Research · 3 Aug 2026neutral

CVS Health is approaching its second-quarter earnings report, with estimates projecting growth in revenue and earnings per share, supported by Aetna initiatives and other key business segments.

Why it matters — CVS watchers would care because the Q2 earnings results will provide insight into whether Aetna initiatives and core business segments are delivering on expected growth.

5 Things to Know Before the Stock Market Opens on Monday

Investopedia · 3 Aug 2026neutral

The excerpt covers a broad market update mentioning higher stock futures, falling oil prices, several upcoming earnings reports, and a potential merger discussion between AstraZeneca and Bristol-Myers Squibb. No specific mention of CVS Health Corp. is included.

Why it matters — While CVS is not directly mentioned, the general market sentiment and earnings season context can influence the broader sector in which CVS operates.

Is It Worth Investing in CVS Health (CVS) Based on Wall Street's Bullish Views?

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research published an article discussing how Wall Street analysts' bullish ratings and recommendation changes can influence investor decisions and stock prices for CVS Health.

Why it matters — CVS watchers care because analyst sentiment and rating changes can affect the stock's price and shape investor perception of the company.

Stay Ahead of the Game With CVS Health (CVS) Q2 Earnings: Wall Street's Insights on Key Metrics

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research previewed CVS Health's Q2 2026 earnings, highlighting that analysts are providing estimates not just for total revenue and earnings but also for specific key business metrics.

Why it matters — The article signals that CVS watchers should pay attention to detailed operational metrics beyond headline numbers when the company reports its second-quarter results.

FAQ

Frequently asked questions about CVS stock

What is the CVS stock price forecast for 2026-2027?

The 28 Wall Street analysts covering CVS Health Corp. have a median 12-month price target of $113, with estimates ranging from $79 to $148. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVS stock a buy right now?

Of the 28 analysts covering CVS Health Corp., 24 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CVS Health Corp. 83 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVS?

As at 1 Aug 2026, CVS Health Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will CVS stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +7.2% from the last close, and Ticker Nerd's factor model ranks CVS Health Corp. 83 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVS stock forecast for 2030?

No analyst covering CVS Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $148 over the next 12 months.

How has CVS stock performed over the past year?

CVS Health Corp. returned +74.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CVS Health Corp. do?

CVS Health Corporation is a leading health solutions company that provides comprehensive healthcare services across multiple segments. It operates through Health Care Benefits, offering health insurance and benefits to millions; Health Services, which includes pharmacy benefit management solutions, medical clinics, virtual care, and in-home services; and Pharmacy and Consumer Wellness, encompassing retail pharmacies and consumer health products.

What is the latest news on CVS?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?". Zacks Investment Research reported that CVS Health has a strong earnings surprise history and currently possesses the two key ingredients for a likely earnings beat in its next quarterly report.

Company

About CVS Health Corp.

CVS Health Corporation is a leading health solutions company that provides comprehensive healthcare services across multiple segments. It operates through Health Care Benefits, offering health insurance and benefits to millions; Health Services, which includes pharmacy benefit management solutions, medical clinics, virtual care, and in-home services; and Pharmacy and Consumer Wellness, encompassing retail pharmacies and consumer health products. These segments enable CVS Health Corporation to deliver integrated care, from prescription management and drug dispensing to primary care and wellness offerings. The company serves individuals, employers, health plans, and government programs, playing a pivotal role in the U.S. healthcare ecosystem by bridging retail pharmacy, insurance, and clinical services. Founded in 1963 and headquartered in Woonsocket, Rhode Island, CVS Health Corporation stands as a key player in retail trade and healthcare services, focusing on accessible and coordinated health solutions in today's market.

CEO Mr. J. David Joyner CEBS · 219,000 employees · United States · https://www.cvshealth.com